ABSTRACT:Metoprolol succinate extended-release tablet is a beta-1 (cardio-selective) adrenoceptorblocking agent formulated to provide controlled and predictable release of metoprolol. Hydrochlorothiazide (HCT) is a well-established diuretic and antihypertensive agent, which promotes natruresis by acting on the distal renal tubule. The pharmacokinetics, efficacy, and safety/tolerability of the antihypertensive combination tablet, metoprolol extended release hydrochlorothiazide, essentially reflect the well-described independent characteristics of each of the component agents. Bi-layer tablet is suitable for sequential release of two drugs in combination, separate two incompatible substances, and also for sustained release tablet in which one layer as immediate release layer as initial dose and second layer as maintenance dose. The aim of present work was to develop a robust formulation of Bi-layer tablets of Metoprolol Succinate Extended Release and Hydrochlorthiazide Immediate Release using methocel as polymer and Cross-carmellosesodium as super disintegrant respectively in two layers. The drug product developed to reduce Hypertension.Metoprolol Succinate is an antihypertensive (cardio selective b-blocker) used in the management of hypertension, angina pectoris and heart failure in doses ranging from 25 mg to 200 mg. Hydrochlorothiazide is a first line diuretic drug of the thiazide class which inhibits the reabsorption of sodium, potassium ions in the nephron of the kidney and produces Antihypertensive effect.